Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Jia, Zhifang ^a   Ding, Yanhua ^a   Tian, Suyan ^a   Niu, Junqi ^a   Jiang, Jing ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; GUANINE; PEGINTERFERON; RIBAVIRIN; THYMINE;

ARTICLE; GENE; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IL28B GENE; META ANALYSIS; MIXED INFECTION; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRAL GENETICS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; RIBAVIRIN;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84866675221     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045698     Document Type: Article

References (54)

1. Lavanchy D, (2009) The global burden of hepatitis C. Liver Int 29 (Suppl 1):: 74-81.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB, (2009) Diagnosis, management, and treatment of hepatitis C:an update. Hepatology 49: 1335-1374.
3. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galle GW, et al. (2009) Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med 361: 580-593.
4. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
5. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, et al. (2008) Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48: 1753-1760.
6. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
7. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
8. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, et al. (2010) An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139: 821-827, 827 e821.
9. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, et al. (2010) Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 24: F23-29.
10. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
11. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, et al. (2010) Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52: 33-37.
12. Lunge VR, da Rocha DB, Beria JU, Tietzmann DC, Stein AT, et al. (2012) IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a southern Brazilian HIV type 1 population. AIDS Res Hum Retroviruses 28: 215-219.
13. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, et al. (2010) Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 138: 108-115.
14. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, et al. (2011) HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 60: 261-267.
15. Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, et al. (2011) Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 54: 408-414.
16. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, et al. (2011) IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 6: e18322.
17. Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, et al. (2011) IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53: 746-754.
18. Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, et al. (2011) Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 6: e17232.
19. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, et al. (2011) Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 54: 439-448.
20. Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, et al. (2011) Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 54: 866-871.
21. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, et al. (2011) Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53: 7-13.
22. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, et al. (2011) IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 33: 1162-1172.
23. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, et al. (2011) Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 53: 1118-1126.
24. Lindh M, Lagging M, Farkkila M, Langeland N, Morch K, et al. (2011) Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 203: 1748-1752.
25. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, et al. (2011) Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 54: 772-780.
26. de Rueda PM, Lopez-Nevot MA, Saenz-Lopez P, Casado J, Martin-Casares A, et al. (2011) Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol 106: 1246-1254.
27. Ladero JM, Martin EG, Fernandez C, Carballo M, Devesa MJ, et al. (2012) Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data. J Gastroenterol Hepatol 27: 279-285.
28. Sarrazin C, Schwendy S, Moller B, Dikopoulos N, Buggisch P, et al. (2011) Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 141: 1656-1664.
29. Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, et al. (2011) IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: a cross-sectional study. PLoS Med 8: e1001092.
30. Beinhardt S, Staettermayer AF, Rutter K, Maresch J, Scherzer TM, et al. (2012) Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias? Hepatology 55: 30-8.
31. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, et al. (2012) An IL28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis c genotype 4. Hepatology 55: 336-342.
32. Howell CD, Gorden A, Ryan KA, Thompson AJ, Ibrahim C, et al. (2012) Single Nucleotide Polymorphism Upstream of Interleukin 28B Associated with Phase 1 and Phase 2 of Early Viral Kinetics in Patients Infected with HCV Genotype 1. J Hepatol 56: 557-563.
33. Umemura T, Joshita S, Yoneda S, Katsuyama Y, Ichijo T, et al. (2011) Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. Antivir Ther 16: 1073-1080.
34. Scherzer TM, Stattermayer AF, Strasser M, Laferl H, Maieron A, et al. (2011) Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology 54: 1518-1526.
35. Miyaaki H, Ichikawa T, Yatsuhashi H, Taura N, Miuma S, et al. (2011) Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin. Hepatol Res 41: 1216-1222.
36. Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, et al. (2011) IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat 18: e325-331.
37. Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, et al. (2011) Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Liver Int 31: 1359-1365.
38. Halfon P, Bourliere M, Ouzan D, Maor Y, Renou C, et al. (2011) A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur J Gastroenterol Hepatol 23: 931-935.
39. Lyoo K, Song MJ, Hur W, Choi JE, Hong SW, et al. (2011) Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol 52: 363-366.
40. Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, et al. (2011) Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol 83: 871-878.
41. Sinn DH, Kim YJ, Lee ST, Gwak GY, Choi MS, et al. (2011) Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol 26: 1374-1379.
42. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, et al. (2011) An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One 6: e20904.
43. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, et al. (2010) Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 51: 788-795.
44. Aparicio E, Parera M, Franco S, Perez-Alvarez N, Tural C, et al. (2010) IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 5: e13771.
45. Rallon NI, Soriano V, Naggie S, Restrepo C, Goldstein D, et al. (2011) IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 25: 1025-1033.
46. Labarga P, Barreiro P, Mira JA, Vispo E, Rallon N, et al. (2011) Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse. AIDS 25: 1131-1133.
47. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, et al. (2011) Interferon-lambda serum levels in hepatitis C. Journal of Hepatology 54: 859-865.
48. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-1896.
49. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120-129 e118.
50. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, et al. (2010) Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138: 2307-2314.
51. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338-1345, 1345 e1331-1337.
52. Liao XW, Ling Y, Li XH, Han Y, Zhang SY, et al. (2011) Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 16: 141-147.
53. Toyoda H, Kumada T, Tada T, Kawaguchi T, Murakami Y, et al. (2011) Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C. J Med Virol 83: 1203-1211.
54. Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, et al. (2011) Genetic variation in Interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol 10: 452-457.